TCR2 Therapeutics

Traded on the St. Petersburg Stock Exchange
TCR2 Therapeutics is a biotechnology company developing T cell hematologic cancer immunotherapies.
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

TCR2 Therapeutics balance sheet

Report period2018 2019 2020 2021 2022 Q1 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

TCR2 Therapeutics cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

TCR2 Therapeutics multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

TCR2 Therapeutics profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
TCR2 Therapeutics assets
TCR2 Therapeutics cash flows
TCR2 Therapeutics news
12.05.2022
TCR2 Therapeutics' GAAP loss for 3 months of 2022 was $29.122 million, up 35.4% from $21.512 million in the prior year.
Source: {source} pictogram investors.tcr2.com
Pictogram next
22.03.2022
TCR2 Therapeutics' GAAP loss for 2021 was $99.807 million, up 48.7% from $67.124 million the previous year.
Source: {source} pictogram investors.tcr2.com
Pictogram next
10.11.2021
TCR2 Therapeutics' GAAP loss for 9M 2021 was $72.068 million, up 48.1% from $48.673 million in the prior year.
Source: {source} pictogram investors.tcr2.com
Pictogram next
02.09.2021
FDA has granted orphan drug status to Gavo-cel from TCR2 Therapeutics. The drug is intended to treat a malignancy called cholangiocarcinoma. The company plans to present the new Phase 1/2 clinical data as part of a presentation at the European Society for Medical Oncology Sept. 17.
Source: {source} pictogram investors.tcr2.com
Pictogram next
All TCR2 Therapeutics news
General information
Company nameTCR2 Therapeutics
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address100 BINNEY STREET CAMBRIDGE MA 02142 617-949-5200
Mailing address100 BINNEY STREET CAMBRIDGE MA 02142
Websitewww.tcr2.com
Information disclosurewww.sec.gov